16,516 Chemed Corporation $CHE Shares Sold by ProShare Advisors LLC

02 Nov 2026, 07:41 by Renee Jackson · The Cerbat Gem

ProShare Advisors LLC decreased its holdings in shares of Chemed Corporation (NYSE:CHE – Free Report) by 23.3% during the 3rd quarter, Holdings Channel reports. The firm owned 54,245 shares of the company’s stock after selling 16,516 shares during the quarter. ProShare Advisors LLC’s holdings in Chemed were worth $27,398,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in CHE. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in Chemed in the second quarter worth approximately $34,000. Versant Capital Management Inc boosted its holdings in shares of Chemed by 7,500.0% during the 2nd quarter. Versant Capital Management Inc now owns 76 shares of the company’s stock worth $35,000 after buying an additional 75 shares in the last quarter. Keating Financial Advisory Services Inc. bought a new position in shares of Chemed during the 2nd quarter worth approximately $36,000. MassMutual Private Wealth & Trust FSB boosted its holdings in shares of Chemed by 65.3% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 81 shares of the company’s stock worth $38,000 after buying an additional 32 shares in the last quarter. Finally, Global Retirement Partners LLC acquired a new stake in shares of Chemed during the 2nd quarter worth approximately $49,000. Institutional investors and hedge funds own 95.85% of the company’s stock.

Chemed Price Performance

Shares of NYSE:CHE opened at $533.99 on Monday. The company has a quick ratio of 1.08, a current ratio of 1.11 and a debt-to-equity ratio of 0.27. Chemed Corporation has a twelve month low of $365.20 and a twelve month high of $562.24. The stock’s 50 day moving average is $514.64 and its 200-day moving average is $462.97. The firm has a market capitalization of $6.95 billion, a price-to-earnings ratio of 25.55, a PEG ratio of 2.03 and a beta of 0.50.

Chemed (NYSE:CHE – Get Free Report) last posted its quarterly earnings results on Tuesday, October 27th. The company reported $6.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.44 by $0.31. The business had revenue of $690.94 million during the quarter, compared to the consensus estimate of $685.04 million. Chemed had a net margin of 10.61% and a return on equity of 35.18%. Chemed’s revenue was up 10.6% compared to the same quarter last year. During the same quarter last year, the firm posted $5.27 EPS. Sell-side analysts forecast that Chemed Corporation will post 24.05 EPS for the current fiscal year.

Chemed Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, September 3rd. Investors of record on Monday, August 17th were issued a dividend of $0.70 per share. This represents a $2.80 annualized dividend and a yield of 0.5%. This is an increase from Chemed’s previous quarterly dividend of $0.60. The ex-dividend date was Monday, August 17th. Chemed’s dividend payout ratio is currently 13.40%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on CHE. Royal Bank Of Canada lifted their price objective on shares of Chemed from $548.00 to $585.00 and gave the company a “sector perform” rating in a research note on Thursday. Bank of America reissued a “neutral” rating on shares of Chemed in a research note on Wednesday, July 29th. Oppenheimer raised their price target on shares of Chemed from $590.00 to $625.00 and gave the stock an “outperform” rating in a report on Thursday. Jefferies Financial Group upgraded shares of Chemed from a “hold” rating to a “buy” rating and upped their price objective for the company from $520.00 to $620.00 in a report on Wednesday. Finally, Weiss Ratings upgraded shares of Chemed from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Three analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, Chemed presently has an average rating of “Hold” and a consensus price target of $603.00.

View Our Latest Research Report on CHE

Insider Buying and Selling at Chemed

In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of Chemed stock in a transaction that occurred on Monday, September 28th. The shares were sold at an average price of $513.45, for a total transaction of $1,026,900.00. Following the transaction, the chief executive officer owned 66,418 shares of the company’s stock, valued at $34,102,322.10. This trade represents a 2.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Spencer S. Lee sold 1,000 shares of the firm’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $541.04, for a total transaction of $541,040.00. Following the sale, the executive vice president owned 13,912 shares of the company’s stock, valued at $7,526,948.48. This trade represents a 6.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 7,000 shares of company stock worth $3,653,060. Company insiders own 3.33% of the company’s stock.

Chemed Company Profile

(Free Report)

Chemed Corporation (NYSE:CHE) is a Cincinnati, Ohio-based company that provides healthcare and residential and commercial services through two operating businesses: VITAS Healthcare and Roto-Rooter. Its operations serve customers primarily in the United States, with Roto-Rooter also providing services in Canada.